Compare PBF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | RYTM |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.8B |
| IPO Year | 2011 | 2017 |
| Metric | PBF | RYTM |
|---|---|---|
| Price | $72.56 | $98.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $36.25 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 3.0M | 457.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 69.78 | 28.34 |
| EPS | ★ 9.22 | N/A |
| Revenue | ★ $24,508,200,000.00 | N/A |
| Revenue This Year | $8.77 | $55.34 |
| Revenue Next Year | N/A | $86.06 |
| P/E Ratio | $8.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.62 | $74.50 |
| 52 Week High | $82.61 | $122.20 |
| Indicator | PBF | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 38.07 |
| Support Level | $34.34 | $82.43 |
| Resistance Level | $74.74 | $99.50 |
| Average True Range (ATR) | 4.14 | 3.71 |
| MACD | -0.52 | -0.65 |
| Stochastic Oscillator | 25.55 | 19.79 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines, and storage facilities. The Logistics segment consists solely of PBFX's operations.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.